trading today, page-39

Thanks Titus for the article, sickens to me to read the success of the Stemline IPO is to trigger a wave of bitoech IPOs this year. KalaBio next up, a good IPO here would build momentum, particularly with the VIX risk index at low low levels.

Also, the Stemline stock was up 18% on the first day.

So the question to me is 1) did we get our pricing wrong by pitching it too high or seeking too much capital 2) was it all a case of absolutely stuffed up timing and 3) is IPO2 looking a lot better now?

Mr Bridges, an update in the near future would be much appreciated.